SLC5A2 and cancer: A previous study demonstrated that CANA decreased glucose uptake in cancer cells in a dose-dependent manner [10], suggesting that the cancer cells, at least in part, depend on SGLT2 for glucose uptake and compensatory mechanisms for glucose uptake may not work after CANA treatment.